Michael J. Kelley

This study reports a 5.4% rate of pathogenic germline variants in a racially diverse cohort of prostate cancer patients, with significant associations between PGV rates and age at diagnosis and self-identified race.

The paper identifies LINE-1 retrotransposition as a cause of MET exon 14 skipping in cancer, leading to actionable mutations.

This study analyzes genomic alterations in metastatic prostate cancer patients across racial groups, finding race-associated differences in mutation frequencies and survival outcomes.